{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05464030",
            "orgStudyIdInfo": {
                "id": "MS202329_0001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-500508-23-00",
                    "type": "OTHER",
                    "domain": "EU CTIS"
                }
            ],
            "organization": {
                "fullName": "EMD Serono",
                "class": "INDUSTRY"
            },
            "briefTitle": "Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)",
            "officialTitle": "A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "anti-adc-in-advanced-solid-tumors-proceade-crc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-27",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-27",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-15",
            "studyFirstSubmitQcDate": "2022-07-15",
            "studyFirstPostDateStruct": {
                "date": "2022-07-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "EMD Serono Research & Development Institute, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck KGaA, Darmstadt, Germany",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2).\n\nStudy details include:\n\n* Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2\n* M9140 is not available through an expanded access program"
        },
        "conditionsModule": {
            "conditions": [
                "Colorectal Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: M9140",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9140"
                    ]
                },
                {
                    "label": "Part 2A: M9140",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9140"
                    ]
                },
                {
                    "label": "Part 2B: M9140",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9140"
                    ]
                },
                {
                    "label": "Part 2C: M9140 + Bevacizumab +/-Capecitabine",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9140",
                        "Drug: Bevacizumab",
                        "Drug: Capecitabine"
                    ]
                },
                {
                    "label": "Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9140",
                        "Drug: 5-fluorouracil (5-FU)",
                        "Drug: Folinic acid"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "M9140",
                    "description": "M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.",
                    "armGroupLabels": [
                        "Part 1: M9140"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "M9140",
                    "description": "M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.",
                    "armGroupLabels": [
                        "Part 2A: M9140",
                        "Part 2B: M9140",
                        "Part 2C: M9140 + Bevacizumab +/-Capecitabine",
                        "Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bevacizumab",
                    "description": "Bevacizumab will be administered intravenously as per standard of care.",
                    "armGroupLabels": [
                        "Part 2C: M9140 + Bevacizumab +/-Capecitabine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "Capecitabine will be administered orally as per standard of care.",
                    "armGroupLabels": [
                        "Part 2C: M9140 + Bevacizumab +/-Capecitabine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "5-fluorouracil (5-FU)",
                    "description": "5-FU will be administered intravenously as per standard of care.",
                    "armGroupLabels": [
                        "Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Folinic acid",
                    "description": "Folinic acid will be administered intravenously as per standard of care.",
                    "armGroupLabels": [
                        "Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)",
                    "timeFrame": "up to 4 months"
                },
                {
                    "measure": "Part 1: Recommended Dose Expansion (RDE) of M9140",
                    "timeFrame": "up to 4 months"
                },
                {
                    "measure": "Parts 2B, 2C and 2D: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)",
                    "timeFrame": "up to 8 months"
                },
                {
                    "measure": "Part 2A: Number of Participants with Adverse Events (AEs)",
                    "timeFrame": "up to 8 months"
                },
                {
                    "measure": "Part 2A: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators",
                    "timeFrame": "Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months"
                },
                {
                    "measure": "Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators",
                    "timeFrame": "Time from first study treatment to planned assessment at approximately 8 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1, 2A, 2B, 2C and 2D: Pharmacokinetic (PK) Plasma Concentrations of M9140",
                    "timeFrame": "Part 1: Pre-dose up to 4 months; Part 2: Pre-dose up to 8 months"
                },
                {
                    "measure": "Parts 1, 2A, 2B, 2C and 2D: Number of Participants with Anti-Drug Antibodies (ADA) Against M9140",
                    "timeFrame": "Part 1: up to 4 months; Part 2: up to 8 months"
                },
                {
                    "measure": "Parts 1, 2A, 2B, 2C and 2D: Levels of Titers of Anti-Drug Antibody (ADA) Against M9140",
                    "timeFrame": "Part 1: up to 4 months; Part 2: up to 8 months"
                },
                {
                    "measure": "Parts 1 and 2A: Number of Participants with Clinically Significant Changes from Baseline in Triplicate 12-Lead Electrocardiogram (ECG)",
                    "timeFrame": "Part 1: up to 4 months; Part 2: up to 8 months"
                },
                {
                    "measure": "Parts 1 and 2A: Change from Baseline in QTc (\u0394QTc) Interval",
                    "timeFrame": "Part 1: baseline, up to 4 months; Part 2: baseline up to 8 months"
                },
                {
                    "measure": "Parts 1, 2B, 2C: and 2D: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators",
                    "timeFrame": "Time from first study treatment throughout the study duration until progressive disease or death up to approximately 4 months and 8 months"
                },
                {
                    "measure": "Parts 1, 2B, 2C and 2D: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator",
                    "timeFrame": "Time from first study treatment to planned assessment at approximately 4 months and 8 months"
                },
                {
                    "measure": "Parts 2A, 2B, 2C and 2D: Time to Response",
                    "timeFrame": "Time from first study treatment to planned assessment at approximately 8 months"
                },
                {
                    "measure": "Parts 1, 2A, 2B, 2C and 2D: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators",
                    "timeFrame": "Time from first study treatment to planned assessment at approximately 4 months and 8 months"
                },
                {
                    "measure": "Part 2A: Overall Survival",
                    "timeFrame": "Time from first study treatment to planned assessment at approximately 8 months"
                },
                {
                    "measure": "Part 2A: Number of Participants with Symptomatic Adverse Events (AEs)",
                    "timeFrame": "up to 8 months"
                },
                {
                    "measure": "Parts 2A, 2B, 2C and 2D: Number of Participants with Disease Control",
                    "timeFrame": "At Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with documented histopathological diagnosis of locally advanced or metastatic colorectal cancer (CRC), who were intolerant/refractory to or progressed after standard systemic therapies for the advanced/metastatic stage, if locally indicated and available to the participant. Participants with a known microsatellite instability high (MSI-H) status must have received treatment with an immune checkpoint inhibitor (if locally indicated and available) unless contraindicated.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1\n* Participants with adequate hematologic, hepatic and renal function as defined in protocol\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years)\n* Participants with known brain metastases, except those meeting the following criteria: Brain metastases that have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment; No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable)\n* Participants with diarrhea (liquid stool) or ileus Grade \\> 1\n* Participants with active chronic inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, intestinal perforation) and/or bowel obstruction\n* Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] \\>= II) or a coronary revascularization procedure within 180 days of study entry. Calculated QTc average (using the Fridericia correction calculation) of \\> 470 milliseconds (ms)\n* Cerebrovascular accident/stroke (\\< 6 months prior to enrollment)\n* Other protocol defined exclusion criteria could apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US Medical Information",
                    "role": "CONTACT",
                    "phone": "888-275-7376",
                    "email": "eMediUSA@emdserono.com"
                },
                {
                    "name": "Communication Center",
                    "role": "CONTACT",
                    "phone": "+49 6151 72 5200",
                    "email": "service@emdgroup.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Responsible",
                    "affiliation": "EMD Serono Research & Development Institute, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "California Cancer Associates for Research & Excellence, Inc.",
                    "status": "RECRUITING",
                    "city": "Encinitas",
                    "state": "California",
                    "zip": "92024",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alberto Bessudo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.03699,
                        "lon": -117.29198
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center - Oncology",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kanwal Raghav",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ismael Rodriguez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "National Cancer Center Hospital - Dept of Gastroenterology",
                    "status": "RECRUITING",
                    "city": "Chuo-ku",
                    "country": "Japan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "kenkato@ncc.go.jp"
                        },
                        {
                            "name": "Ken Kato",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.57779,
                        "lon": 139.71685
                    }
                },
                {
                    "facility": "Kindai University Hospital",
                    "status": "RECRUITING",
                    "city": "Osakasayama-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Hisato Kawakami",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Hospital Clinic de Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Joan Maurel Santasusana",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital del Mar",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Joana Vidal Barrull",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital HM Nou Delfos",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Tatiana Hernandez Guerrero",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron - VHIR",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "egarralda@vhio.net"
                        },
                        {
                            "name": "Elena Garralda Cabanas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Reina Sofia",
                    "status": "RECRUITING",
                    "city": "Cordoba",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Rosa Maria Rodriguez Alonso",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.89155,
                        "lon": -4.77275
                    }
                },
                {
                    "facility": "ICO l'Hospitalet - Hospital Duran i Reynals",
                    "status": "RECRUITING",
                    "city": "L'Hospitalet de Llobregat",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Jose Carlos Ruffinelli Rodriguez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.35967,
                        "lon": 2.10028
                    }
                },
                {
                    "facility": "Centro Integral Oncologico Clara Campal",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Maria Jose de Miguel Luken",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Rocio Garcia Carbonero",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Bernard Gaston Doger de Speville Uribe",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Quironsalud Madrid - NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "vboni@nextoncology.eu"
                        },
                        {
                            "name": "Valentina Boni",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Complejo Hospitalario Universitario de Santiago",
                    "status": "RECRUITING",
                    "city": "Santiago de Compostela",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Rafael Lopez Lopez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88052,
                        "lon": -8.54569
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen del Rocio",
                    "status": "RECRUITING",
                    "city": "Sevilla",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Manuel Valladares Ayerbes",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Trial Awareness and Transparency website",
                    "url": "https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS202329_0001"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002955",
                    "term": "Leucovorin"
                },
                {
                    "id": "D000005492",
                    "term": "Folic Acid"
                },
                {
                    "id": "D000068258",
                    "term": "Bevacizumab"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                },
                {
                    "id": "D000005472",
                    "term": "Fluorouracil"
                },
                {
                    "id": "D000058766",
                    "term": "Levoleucovorin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000014803",
                    "term": "Vitamin B Complex"
                },
                {
                    "id": "D000014815",
                    "term": "Vitamins"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                },
                {
                    "id": "D000006397",
                    "term": "Hematinics"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "asFound": "According",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "asFound": "Non-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29233",
                    "name": "Levoleucovorin",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17558",
                    "name": "Vitamins",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                },
                {
                    "id": "M9485",
                    "name": "Hematinics",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "asFound": "Web-",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}